A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence.
Fabio Salvatore MacalusoJ R Fraser CummingsRaja AtreyaJaeyun ChoiAmbrogio OrlandoPublished in: Expert opinion on biological therapy (2021)
The available analytical and clinical data support the equivalence of SB2 to the reference product across approved indications. This is further supported by emerging real-world evidence, particularly in extrapolated indications such as inflammatory bowel disease for both infliximab-naïve patients and patients already established on infliximab switching to SB2. Switching from originator or biosimilar infliximab to SB2 including both single and multiple switches was not associated with an increased risk of loss of treatment response or any safety or immunogenicity concerns. Overall, the approved infliximab biosimilar SB2 is safe and effective in clinical practice across licensed indications.